Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE ...

Veru Inc (VERU) reports positive Phase 2B study ... significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less ...

Veru is a late clinical-stage biopharmaceutical ... greater than or equal to 60 years of age receiving semaglutide, which is Wegovy, for weight for chronic weight management.

About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant and a ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

The treatment objective is for patients to have a healthier option for choosing to stop GLP-1s without the fear of fat regain,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive ...

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI ...

Veru Inc. updates on its Phase 2b clinical trials ... patients receiving semaglutide (Wegovy Enobosarm + semaglutide treatment resulted in dose dependent greater loss of fat mass compared to ...

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ... significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- - ...